Strong 2021 sales and business EPS (1) growth enabling increased investment in R&D Paris, February 4, 2022 Q4 2021 sales growth of 4.1% and business EPS (1) growth of 9.8% at CER Specialty Care advanced to the largest business unit by sales (€ 3,487 million, +21.3%), driven by Dupixent ® (+53.1%) Vaccines -6.5% despite strong Europe sales, reflecting low 2021 U.S. influenza vaccination rates and record shipments in Q3 General Medicines core assets up 2.1%, while GBU sa
February 4, 2022
· 73 min read